SPARC196.80

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹6,386 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations75.671.81,879.21,909.5
Other Income29.51.811.025.5
Total Income105.073.61,890.11,934.9
Expenses
+ Cost of Materials Consumed28.123.123.626.1
+ Employee Benefit Expense141.8153.6118.0116.3
+ Finance Costs1.79.034.136.1
+ Depreciation & Amortisation12.512.410.29.7
+ Other Expenses307.7218.2138.8150.2
Total Expenses491.9416.3324.8338.4
EBITDA-402.1-323.11,598.81,616.8
EBIT-414.6-335.51,588.61,607.1
Profit
PBT before Exceptional Items-386.8-342.81,565.41,596.5
+ Exceptional Items0.00.0-12.4-12.4
Pretax Income-386.8-342.81,553.01,584.2
+ Current Tax1.6-0.3-0.2-0.3
+ Deferred Tax-1.30.00.00.2
Tax Expense0.4-0.3-0.2-0.1
Net Income-387.2-342.51,553.21,584.3
+ Net Income — Continuing Ops-387.2-342.51,553.21,584.3
+ Other Comprehensive Income0.2-0.22.62.6
Total Comprehensive Income-387.0-342.71,555.81,586.9
Net Income to Common-342.71,555.8
Per Share
Basic EPS-11.93-10.5547.8648.81
Diluted EPS-11.93-10.550.00-5.46
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.22.62.6
+ Items NOT to be Reclassified to P&L2.6
+ Tax on Items NOT to be Reclassified0.30.00.0
+ Tax on Items NOT to be Reclassified — alt tag-0.2
+ Tax on Items to be Reclassified-0.1
+ Tax on Items to be Reclassified — alt tag-0.0
Comprehensive Income — Owners of Parent0.0-0.22.6
Per Share — as-filed variants
Basic EPS — Continuing Operations-11.93-10.5547.8648.81
Diluted EPS — Continuing Operations-11.93-10.550.00-5.46
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit47.448.71,855.61,883.3
Gross Margin %62.7767.7998.7498.63
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-386.8-342.81,565.41,596.5
− Exceptional Items (reconciliation)0.00.0-12.4-12.4
Net Income Adj (tax-effected)-387.2-342.51,565.61,596.7
EPS Adj-11.93-10.5548.2449.19
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital32.532.532.532.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.